Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections

Sarah C. Vick, Marie Frutoso, Florian Mair, Andrew J. Konecny, Evan Greene, Caitlin R. Wolf, Jennifer K. Logue, Jim Boonyaratanakornkit, Raphael Gottardo, Joshua T. Schiffer, Helen Y. Chu, View ORCID ProfileMartin Prlic, View ORCID ProfileJennifer M. Lund
doi: https://doi.org/10.1101/2021.03.25.21254376
Sarah C. Vick
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Frutoso
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Mair
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Konecny
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan Greene
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caitlin R. Wolf
2Department of Medicine, University of Washington, Seattle, WA, 98195
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer K. Logue
2Department of Medicine, University of Washington, Seattle, WA, 98195
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Boonyaratanakornkit
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
2Department of Medicine, University of Washington, Seattle, WA, 98195
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphael Gottardo
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua T. Schiffer
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
2Department of Medicine, University of Washington, Seattle, WA, 98195
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Y. Chu
2Department of Medicine, University of Washington, Seattle, WA, 98195
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Prlic
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
3Department of Immunology, University of Washington, Seattle, WA, 98195
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin Prlic
  • For correspondence: mprlic@fredhutch.org jlund@fredhutch.org
Jennifer M. Lund
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
4Department of Global Health, University of Washington, Seattle, WA 98195
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer M. Lund
  • For correspondence: mprlic@fredhutch.org jlund@fredhutch.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 infection has caused a lasting global pandemic costing millions of lives and untold additional costs. Understanding the immune response to SARS-CoV-2 has been one of the main challenges in the past year in order to decipher mechanisms of host responses and interpret disease pathogenesis. Comparatively little is known in regard to how the immune response against SARS-CoV-2 differs from other respiratory infections. In our study, we compare the peripheral blood immune signature from SARS-CoV-2 infected patients to patients hospitalized pre-pandemic with Influenza Virus or Respiratory Syncytial Virus (RSV). Our in-depth profiling indicates that the immune landscape in patients infected by SARS-CoV-2 is largely similar to patients hospitalized with Flu or RSV. Similarly, serum cytokine and chemokine expression patterns were largely overlapping. Unique to patients infected with SARS-CoV-2 who had the most critical clinical disease state were changes in the regulatory T cell (Treg) compartment. A Treg signature including increased frequency, activation status, and migration markers was correlated with the severity of COVID-19 disease. These findings are particularly relevant as Tregs are being discussed as a therapy to combat the severe inflammation seen in COVID-19 patients. Likewise, having defined the overlapping immune landscapes in SARS-CoV-2, existing knowledge of Flu and RSV infections could be leveraged to identify common treatment strategies.

Highlights

  1. The immune landscapes of hospitalized pre-pandemic RSV and influenza patients are similar to SARS-CoV-2 patients

  2. Serum cytokine and chemokine expression patterns are largely similar between patients hospitalized with respiratory virus infections, including SARS-CoV-2, versus healthy donors

  3. SARS-CoV-2 patients with the most critical disease displayed unique changes in the Treg compartment

  4. advances in understanding and treating SARS-CoV-2 could be leveraged for other common respiratory infections

Figure1
  • Download figure
  • Open in new tab

Competing Interest Statement

R.G. has received consulting income from Takeda and Merck and declares ownership in Ozette Technologies. E.G declares ownership in Ozette Technologies.

Funding Statement

This work was supported by NIH grant R01 AI121129 and R01 AI141435.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies were approved by the University of Washington Human Subjects Institutional Review Board, IRB numbers STUDY00000959 and STUDY00002929.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

We provide much of the raw data in the form of Supplementary Tables. Additional data can be provided upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections
Sarah C. Vick, Marie Frutoso, Florian Mair, Andrew J. Konecny, Evan Greene, Caitlin R. Wolf, Jennifer K. Logue, Jim Boonyaratanakornkit, Raphael Gottardo, Joshua T. Schiffer, Helen Y. Chu, Martin Prlic, Jennifer M. Lund
medRxiv 2021.03.25.21254376; doi: https://doi.org/10.1101/2021.03.25.21254376
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections
Sarah C. Vick, Marie Frutoso, Florian Mair, Andrew J. Konecny, Evan Greene, Caitlin R. Wolf, Jennifer K. Logue, Jim Boonyaratanakornkit, Raphael Gottardo, Joshua T. Schiffer, Helen Y. Chu, Martin Prlic, Jennifer M. Lund
medRxiv 2021.03.25.21254376; doi: https://doi.org/10.1101/2021.03.25.21254376

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (202)
  • Anesthesia (55)
  • Cardiovascular Medicine (497)
  • Dentistry and Oral Medicine (91)
  • Dermatology (57)
  • Emergency Medicine (170)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (220)
  • Epidemiology (5770)
  • Forensic Medicine (3)
  • Gastroenterology (223)
  • Genetic and Genomic Medicine (888)
  • Geriatric Medicine (89)
  • Health Economics (234)
  • Health Informatics (777)
  • Health Policy (401)
  • Health Systems and Quality Improvement (259)
  • Hematology (108)
  • HIV/AIDS (188)
  • Infectious Diseases (except HIV/AIDS) (6605)
  • Intensive Care and Critical Care Medicine (398)
  • Medical Education (120)
  • Medical Ethics (29)
  • Nephrology (94)
  • Neurology (863)
  • Nursing (46)
  • Nutrition (145)
  • Obstetrics and Gynecology (166)
  • Occupational and Environmental Health (268)
  • Oncology (521)
  • Ophthalmology (169)
  • Orthopedics (44)
  • Otolaryngology (108)
  • Pain Medicine (49)
  • Palliative Medicine (22)
  • Pathology (150)
  • Pediatrics (258)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (116)
  • Psychiatry and Clinical Psychology (997)
  • Public and Global Health (2271)
  • Radiology and Imaging (381)
  • Rehabilitation Medicine and Physical Therapy (176)
  • Respiratory Medicine (315)
  • Rheumatology (111)
  • Sexual and Reproductive Health (84)
  • Sports Medicine (83)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (35)
  • Urology (42)